1
|
Shadyab AH, LaCroix AZ, Matthews G, Bennett D, Shadyab AA, Tan D, Thomas RG, Mason J, Lopez A, Askew B, Donahue L, Kaplita S, Qureshi IA, Huisa B, Feldman HH. T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease. Alzheimers Dement (N Y) 2022; 8:e12265. [PMID: 35310528 PMCID: PMC8919121 DOI: 10.1002/trc2.12265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 11/02/2021] [Accepted: 01/10/2022] [Indexed: 12/02/2022]
Abstract
Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much-needed therapeutic progress. Methods T2 Protect AD (T2), a phase 2 randomized placebo-controlled trial of troriluzole in mild to moderate AD, used multiple recruitment strategies. Results T2 exceeded its recruitment target, enrolling 350 participants between July 2018 and December 2019 (randomization rate: 0.87 randomizations/site/month, or 3-fold greater than recent trials of mild to moderate AD). The vast majority (98%) of participants were enrolled during a 10-month window of intense promotion in news media, TV and radio advertisements, and social media. The distribution of primary recruitment sources included: existing patient lists at participating sites (72.3%), news media (12.3%), physician referral (6.0%), word of mouth (3.1%), and paid advertising (2.9%). Discussion The rapid recruitment of participants with mild to moderate AD was achieved through a range of approaches with varying success.
Collapse
Affiliation(s)
- Aladdin H. Shadyab
- Herbert Wertheim School of Public Health and Human Longevity ScienceUniversity of California, San DiegoLa JollaCaliforniaUSA
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Andrea Z. LaCroix
- Herbert Wertheim School of Public Health and Human Longevity ScienceUniversity of California, San DiegoLa JollaCaliforniaUSA
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Genevieve Matthews
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Daniel Bennett
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Alexandre A. Shadyab
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Donna Tan
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Ronald G. Thomas
- Herbert Wertheim School of Public Health and Human Longevity ScienceUniversity of California, San DiegoLa JollaCaliforniaUSA
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Jennifer Mason
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Alex Lopez
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Brianna Askew
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Lia Donahue
- Biohaven Pharmaceuticals, Inc.New HavenConnecticutUSA
| | | | | | - Branko Huisa
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | - Howard H. Feldman
- Alzheimer's Disease Cooperative StudyUniversity of California, San DiegoLa JollaCaliforniaUSA
| | | |
Collapse
|
2
|
Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targeting Prodromal Alzheimer Disease With Avagacestat. JAMA Neurol 2015; 72:1324-33. [DOI: 10.1001/jamaneurol.2015.0607] [Citation(s) in RCA: 143] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Vladimir Coric
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Stephen Salloway
- Department of Neurology, Brown Medical School, Butler Hospital, Providence, Rhode Island
| | | | - Bruno Dubois
- Dementia Research Center, Department of Neurology, Cognition, Neuro-imagerie et maladies du Cerveau, University Pierre et Marie Curie Paris 6, Hôpital de la Salpétrière, Paris, France
| | - Niels Andreasen
- Department of Neurobiology, Karolinska Institute, Stockholm, Sweden
| | - Mark Brody
- Brain Matters Research, Delray Beach, Florida
| | | | - Hilkka Soininen
- Department of Neurology, University of Eastern Finland, Kuopio, Finland
| | | | - Thomas Shiovitz
- California Neuroscience Research Medical Group Inc, Sherman Oaks
| | - Gary Pilcher
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Steven Ferris
- Department of Psychiatry, New York University Langone Medical Center, New York
| | - Susan Colby
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Wendy Kerselaers
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Randy Dockens
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Holly Soares
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Stephen Kaplita
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Feng Luo
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | | | | | - Mark Mintun
- Avid Radiopharmaceuticals, Philadelphia, Pennsylvania
| | - Joshua D. Grill
- Mary S. Easton Center for Alzheimer’s Disease Research, University of California at Los Angeles
| | - Ken Marek
- Institute for Neurodegenerative Disorders, New Haven, Connecticut
| | - John Seibyl
- Institute for Neurodegenerative Disorders, New Haven, Connecticut
| | - Jesse M. Cedarbaum
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | - Charles Albright
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| | | | - Robert M. Berman
- Global Clinical Research, Bristol-Myers Squibb, Wallingford, Connecticut
| |
Collapse
|
3
|
Istace A, Bracoud L, Berman RM, Luo F, Roche F, Salloway S, Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Ferris SH, Grill JD, Gouttard S, Schaerer J, Hayes W, Kaplita S, Belaroussi B, Yu HJ, Cedarbaum J, Feldman H, Pachai C, Coric V. P2‐202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.05.879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
| | | | | | - Feng Luo
- Bristol Myers SquibbPrincetonNew JerseyUnited States
| | | | - Stephen Salloway
- Brown Medical School, Butler HospitalProvidenceRhode IslandUnited States
| | - Christopher Dyck
- Yale, Alzheimer's Disease Research UnitNew HavenConnecticutUnited States
| | | | | | - Mark Brody
- Brain Matters Research, Inc.Delray BeachFloridaUnited States
| | - Craig Curtis
- Compass Research, LLCOrlandoFloridaUnited States
| | | | - Stephen Thein
- Pacific Research Network IncSan DiegoCaliforniaUnited States
| | - Thomas Shiovitz
- California Neuroscience Research Medical Group, IncSherman OaksCaliforniaUnited States
| | | | - Joshua D. Grill
- UCLA Easton Alzheimer's Disease Research CenterLos AngelesCaliforniaUnited States
| | | | | | - Wendy Hayes
- Bristol‐Myers SquibbPrincetonNew JerseyUnited States
| | | | | | | | | | - Howard Feldman
- University of British Columbia HospitalVancouverBritish ColumbiaCanada
| | | | - Vlad Coric
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| |
Collapse
|
4
|
Istace A, Bracoud L, Berman RM, Luo F, Roche F, Salloway S, Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Ferris SH, Grill JD, Gouttard S, Schaerer J, Hayes W, Kaplita S, Belaroussi B, Yu HJ, Cedarbaum J, Feldman H, Pachai C, Coric V. IC‐P‐108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.05.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
| | | | | | - Feng Luo
- Bristol Myers SquibbPrincetonNew JerseyUnited States
| | | | - Stephen Salloway
- Brown Medical School, Butler HospitalProvidenceRhode IslandUnited States
| | - Christopher Dyck
- Yale University School of MedicineNew HavenConnecticutUnited States
| | | | | | - Mark Brody
- Brain Matters Research, Inc.Delray BeachFloridaUnited States
| | - Craig Curtis
- Compass Research, LLCOrlandoFloridaUnited States
| | | | - Stephen Thein
- Pacific Research Network IncSan DiegoCaliforniaUnited States
| | - Thomas Shiovitz
- California Neuroscience Research Medical Group, IncSherman OaksCaliforniaUnited States
| | - Steven H. Ferris
- California Neuroscience Research Medical Group, IncSherman OaksCaliforniaUnited States
| | - Joshua D. Grill
- UCLA Easton Alzheimer's Disease Research CenterLos AngelesCaliforniaUnited States
| | | | | | - Wendy Hayes
- Bristol‐Myers SquibbPrincetonNew JerseyUnited States
| | | | | | | | | | - Howard Feldman
- University of British Columbia HospitalVancouverBritish ColumbiaCanada
| | | | - Vlad Coric
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| |
Collapse
|
5
|
Preston J, Berman R, Kaplita S, Gandhi KK, Lipschitz A, Tiller J, Yogendran L, Hodson DS, Coric V. P1–340: Safety and tolerability of avagacestat (BMS‐708163) in people with predementia Alzheimer's disease: Association with nonmelanoma skin cancer. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - Robert Berman
- Bristol‐Myers Squibb Wallingford Connecticut United States
| | | | | | | | - Jane Tiller
- Bristol‐Myers Squibb Lawrenceville New Jersey United States
| | | | - Darryl S. Hodson
- Georgia Dermatology and Skin Cancer Center Dublin Georgia United States
| | - Vlad Coric
- Bristol‐Myers Squibb Wallingford Connecticut United States
| |
Collapse
|
6
|
Coric V, Salloway S, Dyck C, Kerselaers W, Kaplita S, Curtis C, Ross J, Richter RW, Andreasen N, Brody M, Sharma SK, Cedarbaum JM, Berman R. P1–343: A phase II study of the gamma‐secretase inhibitor avagacestat (BMS‐708163) in predementia Alzheimer's disease. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.569] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Vlad Coric
- Bristol‐Myers Squibb R&D Wallingford Connecticut United States
| | | | - Christopher Dyck
- Yale University School of Medicine New Haven Connecticut United States
| | | | - Stephen Kaplita
- Bristol‐Myers Squibb R&D Wallingford Connecticut United States
| | - Craig Curtis
- Compass Research, LLC Orlando Florida United States
| | - Joel Ross
- Memory Enhancement Center of New Jersey Toms River New Jersey United States
| | | | - Niels Andreasen
- Karolinska Institute, Alzheimer's Disease Research Center Memory Clinic M51, Karolinska University Hospital Huddinge Sweden
| | - Mark Brody
- Brain Matters Research Delray Beach Florida United States
| | - Sanjiv K. Sharma
- Memory Enhancement Center of New Jersey Toms River New Jersey United States
| | | | - Robert Berman
- Bristol‐Myers Squibb R&D Wallingford Connecticut United States
| |
Collapse
|
7
|
AbuTarif M, Kaplita S, Berman R, Coric V, Colby S, Baron K. P3‐416: Avagacestat (BMS‐708163) exposures and study discontinuations in patients with mild‐to‐moderate Alzheimer's disease. Alzheimers Dement 2012. [DOI: 10.1016/j.jalz.2012.05.2090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Malaz AbuTarif
- Bristol‐Myers SquibbLawrencevilleNew JerseyUnited States
| | | | - Robert Berman
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Vlad Coric
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Susan Colby
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Kyle Baron
- Metrum Research Group LLCTariffvilleConnecticutUnited States
| |
Collapse
|
8
|
Burns L, Berman R, Guo Z, Soares H, Kaplita S, Yoo B, Donohue M. P1‐300: The relationship between cerebral spinal fluid (CSF) biomarkers and Pittsburgh Compound B (PiB) positron emission tomography (PET) in predicting Alzheimer's disease (AD). Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- Leah Burns
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Robert Berman
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Zhenchao Guo
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Holly Soares
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | | | - Bongin Yoo
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Michael Donohue
- University of CaliforniaLa JollaSan DiegoCaliforniaUnited States
| |
Collapse
|
9
|
Feldman H, Coric V, Sperling R, Greenberg S, Bronen R, Sorensen AG, Salloway S, Pachai C, Kaplita S, Meadowcroft M, Albright C, Berman R. P2‐195: Cerebral microbleeds in a phase 2 clinical trial of mild‐to‐moderate Alzheimer's disease with the gamma secretase inhibitor BMS‐708163. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
| | - Vlad Coric
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| | - Reisa Sperling
- Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUnited States
| | - Steven Greenberg
- Massachusetts General Hospital and Harvard Medical SchoolBostonMassachusettsUnited States
| | - Richard Bronen
- Yale University School of MedicineNew HavenConnecticutUnited States
| | | | - Stephen Salloway
- Butler Hospital, The Warren Alpert Medical School of Brown UniversityProvidenceRhode IslandUnited States
| | | | | | | | | | - Robert Berman
- Bristol‐Myers SquibbWallingfordConnecticutUnited States
| |
Collapse
|
10
|
Burns L, L'Italien G, Guo Z, Lapuerta P, Risinger R, Berman RM, Kaplita S, Hill D, Feldman H, Rueckert D, Donohue M. P1‐384: Predicting time to dementia based on selected MRI volumetrics and CSF measures. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Leah Burns
- Bristol - Myers SquibbWallingford CT USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Risinger R, Berman RM, Coric V, Han J, Kaplita S, Burns L, Bhagwagar Z, Hill D, Wolz R, Rueckert D, Feldman H. P1‐387: Mild to moderate Alzheimer's disease (AD) clinical trials: The role of hippocampal atrophy as an inclusion criterion. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
| | | | - Vlad Coric
- Bristol - Myers SquibbWallingford CT USA
| | - Jian Han
- Bristol - Myers SquibbWallingford CT USA
| | | | - Leah Burns
- Bristol - Myers SquibbWallingford CT USA
| | | | | | | | | | | |
Collapse
|
12
|
Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8503] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8503 Background: Tanespimycin (Tan) disrupts HSP90, a key molecular chaperone for signal transduction proteins critical to myeloma (MM) growth, survival and drug resistance. Preclinical data show anti-tumor synergy between Tan and bortezomib (Bz) and suggest Tan may be neuroprotective, including reversibility of Bz-induced peripheral neuropathy (PN). A phase I study of single agent Tan in advanced MM showed favorable tolerability and modest activity. Methods: 72 patients (pts) with relapsed/refractory MM received 0.7 - 1.3 mg/m2 Bz as IVB followed by 1-hr infusion of 100 -340 mg/m2 Tan on days 1, 4, 8,11 q 21d, with 42 pts receiving the highest dose of both drugs as part of a phase II expansion. Toxicities were assessed by CTCAE v3 and response by modified EBMT criteria. Results: Of 72 pts, 72% had IgG subtype with a median age of 60 yo. Median time since MM diagnosis was 50 mos with median of 5 (1–15) prior regimens. Prior treatments included stem cell transplant (69%), thalidomide (74%), Bz (69%), lenalidomide (28%) and Hsp90 inhibitors (13%). 58 pts with measurable disease were treated at 1 or 1.3 mg/m2 Bz. Response rates (≥ MR) were 41%, 20% and 14% in the Bz-naive, -pretreated and -refractory pts respectively. In the subgroup with 1–3 prior therapies and who were Bz-naive, the response rate was 56%. Median duration of response (DOR) for all pts with response (n=14) was 10.7 mos, including 3 Bz-refractory pts who had durable PR through mos 12, 22 and 28. 3 other pts remain in response through 24 mos. Of the 72 pts, the most frequent AEs were diarrhea (60%), nausea (49%), fatigue (49%), thrombocytopenia (40%) and AST elevation (28%), which proved manageable with dose reduction and supportive care. Most frequent G3–4 AEs included thrombocytopenia (25%), diarrhea, anemia and fatigue (7% each), as well as back pain and AST elevation (4% each). Only 21% of pts had G1–2 PN; no G3–4 PN was seen. Conclusions: Tan + Bz is active and well tolerated in relapsed/refractory MM, with durable responses in Bz-naive, -pretreated and -refractory pts. Median DOR for the combination compares favorably to Bz monotherapy. Final PFS data will be presented. No severe PN has been observed, consistent with Tan's neuroprotective effect in pre-clinical models. A phase III study of Tan + Bz vs Bz is ongoing. [Table: see text]
Collapse
Affiliation(s)
- P. G. Richardson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - A. Chanan-Khan
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - S. Lonial
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - A. Krishnan
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - M. Carroll
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - M. Alsina
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - M. Albitar
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - D. Berman
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - S. Kaplita
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| | - K. Anderson
- Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Emory University School of Medicine, Atlanta, GA; City of Hope Comprehensive Cancer Center, Duarte, CA; Sutter Regional Cancer Institute, Sacramento, CA; Moffitt Cancer Center, Tampa, FL; Quest Diagnostics, Nichols Institute, San Juan Capistrano, CA; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT
| |
Collapse
|
13
|
Peyro-Saint-Paul H, Loze JY, Kaplita S, Han J, Baker R, Cahn R, Owen R. Evaluation of Dyslipidaemia Risk among Patients Treated with Aripiprazole: Meta Analysis of Placebo- and Olanzapine-controlled Studies. Eur Psychiatry 2009. [DOI: 10.1016/s0924-9338(09)71251-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Aims:To evaluate dyslipidaemia risk among patients with schizophrenia treated with aripiprazole or olanzapine.Methods:Pooled analysis of the aripiprazole clinical database, including studies of ≥7 days with at least an oral aripiprazole monotherapy arm. Mean changes from baseline to endpoint and shifts from normal to abnormal lipid levels were calculated.Results:Seventeen placebo- and five olanzapine-controlled studies (3 weeks->3 years) of adult patients (≥18 years) were included. Mean changes (LOCF) in lipids were similar between aripiprazole and placebo for all lipid parameters; aripiprazole showed significant improvements versus olanzapine (p≤0.01). the incidence (OC) of switching to abnormal lipid levels from baseline normal was similar between placebo and aripiprazole, and significantly lower with aripiprazole than olanzapine for most measures.Conclusion:Despite limitations inherent to pooled analyses, these findings lend further support to the differential profile of atypicals, with aripiprazole showing effects on lipids comparable with placebo.
Collapse
|
14
|
Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20:536-46. [PMID: 16401666 DOI: 10.1177/0269881106059693] [Citation(s) in RCA: 164] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
This study compares the efficacy, safety, and tolerability of a partial dopamine agonist, aripiprazole, with placebo in the treatment of patients with bipolar I disorder experiencing an acute manic or mixed episode. In total, 272 hospitalized patients were randomized to aripiprazole 30 mg/day or placebo in this 3-week, double-blind, placebo-controlled trial. Dosing could be reduced to 15 mg/day for tolerability and, subsequently, increased to 30 mg/day based on clinical response. Primary efficacy measure was mean change from baseline to endpoint in Young Mania Rating Scale (YMRS) total score; response was defined as > or = 50% decrease from baseline YMRS score. Aripiprazole-treated patients demonstrated significantly greater improvement from baseline to endpoint in mean YMRS total scores compared with placebo-treated patients as early as Day 4 and sustained through Week 3. A significantly higher response rate was observed in aripiprazole-treated patients (53% vs. 32% at endpoint). Aripiprazole produced significantly greater improvements from baseline on other efficacy assessments compared with placebo, including Clinical Global Impression - Bipolar Version Severity and Improvement scores. The 30 mg/day dose was maintained by 85% of aripiprazole-treated patients. Incidence of discontinuations due to adverse events was similar for aripiprazole (8.8%) and placebo (7.5%). Aripiprazole treatment resulted in no significant difference from placebo in change in mean body weight and was not associated with elevated serum prolactin or QTc prolongation. In conclusion, aripiprazole demonstrated superior efficacy to placebo in the treatment of patients with bipolar I disorder presenting with acute manic or mixed episodes, and exhibited a favourable safety and tolerability profile.
Collapse
Affiliation(s)
- Gary Sachs
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA 2114, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-36. [PMID: 12729864 DOI: 10.1016/s0920-9964(03)00050-1] [Citation(s) in RCA: 310] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Aripiprazole is a novel antipsychotic with a unique mechanism of action. Presented here is a pooled analysis of safety and tolerability data from all completed short-term, placebo-controlled trials in schizophrenia from the aripiprazole clinical development program. Data were analyzed from five 4- to 6-week double-blind multicenter studies of patients hospitalized with acute relapse of schizophrenia or schizoaffective disorder randomized to aripiprazole (n=932), placebo (n=416), or haloperidol (n=201). Daily aripiprazole doses ranged from 2 to 30 mg. Safety assessments included adverse event (AE) reports, EPS scales, ECGs, weight, and prolactin, glucose and cholesterol levels. Aripiprazole was well tolerated, with similar AE incidence rates to placebo, and lower rates than haloperidol for akathisia, extrapyramidal syndrome and somnolence. Objective EPS assessments demonstrated no significant differences between aripiprazole and placebo on Simpson-Angus Scale (SAS) scores, no dose-dependent effects on Barnes Akathisia scores, and significant reductions in Abnormal Involuntary Movement Scale (AIMS) scores from baseline vs. placebo (p</=0.01). Haloperidol showed increased SAS and Barnes Akathisia scores over placebo (p</=0.01). There was minimal mean weight change with aripiprazole (+0.71 kg) and haloperidol (+0.56 kg), and a lack of QT(c) prolongation. Serum prolactin increased with haloperidol, but not aripiprazole. In conclusion, aripiprazole shows a favorable safety and tolerability profile with low potential for EPS, weight gain, prolactin elevation, QT(c) prolongation, and sedation. Aripiprazole's safety profile may offer benefits in schizophrenia treatment.
Collapse
Affiliation(s)
- Stephen R Marder
- Department of Psychiatry, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, 90024, Los Angeles, CA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
In previous uncontrolled studies, nefazodone, a new antidepressant drug, increased REM sleep or had no effect on REM sleep. We report a double-blind, placebo-controlled, parallel group study on effects of nefazodone (N) on polysomnographic sleep variables in healthy human volunteers. Nefazodone was administered for 16 consecutive days, and nocturnal sleep, as well as multiple sleep latency test (MSLT), was monitored before, during, and after N administration. We found that N had no effect on any measured REM sleep variable including REM sleep duration, REM density, and nocturnal REM sleep distribution. Nefazodone also had no significant effect on nocturnal total sleep time or NREM variables, but increased daytime alertness measured by the MSLT. Since N is a potent serotonin reuptake blocker, the present findings that N had no effect on REM sleep cast doubt on the hypothesis that antidepressant drugs decrease REM sleep by increasing serotonergic neurotransmission. A review of other relevant work also casts doubt on this hypothesis.
Collapse
Affiliation(s)
- G Vogal
- Sleep Research Laboratory, Inc., Atlanta, GA. USA
| | | | | | | | | |
Collapse
|
17
|
Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55:234-41. [PMID: 8071277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Nefazodone is a 5-HT2-receptor antagonist and serotonin (5-HT) selective reuptake inhibitor. This study evaluates the safety and efficacy of nefazodone in patients with major depressive disorder (MDD) in comparison to imipramine and placebo treatments. It also compares two dose ranges of nefazodone to investigate its optimal dose range. METHOD Nefazodone was evaluated in a 6-week, double-blind trial of novel design involving 180 patients meeting Research Diagnostic Criteria for major depressive disorder and having a minimum pretreatment score of 22 on the first 17 items of the Hamilton Rating Scale for Depression (HAM-D). Patients were randomly assigned to placebo (2-10 capsules/day), imipramine (50-250 mg/day), or nefazodone in two dose ranges (50-250 mg/day or 100-500 mg/day). RESULTS Improvement on depression measures with nefazodone in the 100-500-mg/day dose range (endpoint mean = 460 mg/day) and imipramine (endpoint mean = 214 mg/day) exceeded that with placebo. Some benefit was also observed in the nefazodone 50-250-mg/day treatment group (endpoint mean = 242 mg/day), but it was suboptimal. Evidence of nefazodone's efficacy as an antidepressant was consistently observed on physician- (HAM-D, Clinical Global Impressions [CGI]) and patient-rated (CGI-patient rated) scales. By patient self-report, improvement of anxiety symptoms associated with depression was evident with nefazodone as early as the first week of treatment, and benefit was seen with both nefazodone dosage groups. Analyses of the physician's global assessments of therapeutic effect and side effects at end of treatment showed therapeutic benefit for both nefazodone and imipramine treatments; however, patients in the nefazodone treatment groups were significantly less troubled by adverse experiences than were imipramine-treated patients, resulting in a lower dropout rate for adverse experience. CONCLUSION Nefazodone is a well-tolerated and effective antidepressant for the treatment of major depressive disorder.
Collapse
Affiliation(s)
- R Fontaine
- Louis-H. Lafontaine Hospital, Research Centre, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | |
Collapse
|